Skip to main content
    I

    Immuneering Corp (IMRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.52
    -0.19 (-5.12%)

    Market Cap: $240.27M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immuneering Corp (IMRX) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Immuneering reported EPS of -$0.37, below the -$0.29 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(13/23)
    Avg Surprise
    +0.70%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.35
    Range-$0.44 - -$0.30
    9 analysts
    Revenue Consensus
    N/A
    RangeN/A
    9 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.40
    Range-$0.41 - -$0.38
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.33-22.1%
    60d ago-$0.34-16.7%
    30d ago-$0.34-16.7%
    7d ago-$0.37-6.3%
    Current-$0.40
    Revenue Consensus
    N/A
    RangeN/A
    4 analysts

    Next Report

    IMRX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    IMRX Earnings Call

    The latest IMRX earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, IMRX beat 13, missed 9 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 137.78% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.37-$0.29-$0.37 - -$0.27-27.59%MissN/A71 up, 2 downOct 29, 2026N/A
    Jun 30, 2026-$0.27-$0.26-$0.31 - -$0.24-3.85%MissN/A72 up, 2 downAug 5, 2026N/A
    Mar 31, 2026-$0.21-$0.35N/A+40.00%BeatN/A53 up, 0 downMay 15, 2026N/A
    Dec 31, 2025-$0.18-$0.31-$0.37 - -$0.23+41.94%BeatN/A6N/AMar 6, 2026N/A
    Sep 30, 2025-$0.38-$0.39-$0.48 - -$0.29+2.56%BeatN/A62 up, 2 downNov 12, 2025N/A
    Jun 30, 2025-$0.40-$0.40-$0.48 - -$0.300.00%In lineN/A51 up, 0 downAug 13, 2025N/A
    Mar 31, 2025-$0.42-$0.58-$0.66 - -$0.51+27.59%BeatN/A21 up, 0 downMay 5, 2025N/A
    Dec 31, 2024-$1.07-$0.45-$0.73 - -$0.23-137.78%MissN/A40 up, 0 downMar 20, 2025$726326
    Sep 30, 2024-$0.49-$0.55-$0.60 - -$0.49+10.91%BeatN/A70 up, 0 downNov 13, 2024N/A
    Jun 30, 2024-$0.47-$0.53-$0.56 - -$0.47+11.32%BeatN/A60 up, 0 downAug 6, 2024N/A
    Mar 31, 2024-$0.49-$0.50-$0.59 - -$0.22+2.00%BeatN/A70 up, 0 downMay 7, 2024N/A
    Dec 31, 2023-$0.52-$0.47-$0.53 - -$0.37-10.64%MissN/A91 up, 0 downMar 1, 2024N/A
    Sep 30, 2023-$0.43-$0.49-$0.56 - -$0.44+12.24%BeatN/A80 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.43-$0.53-$0.62 - -$0.48+18.87%BeatN/A80 up, 0 downAug 3, 2023N/A
    Mar 31, 2023-$0.51-$0.56-$0.63 - -$0.52+8.93%BeatN/A80 up, 0 downMay 4, 2023N/A
    Dec 31, 2022-$0.50-$0.58-$0.61 - -$0.54+13.79%BeatN/A70 up, 0 downMar 6, 2023$455
    Sep 30, 2022-$0.49-$0.48-$0.54 - -$0.41-2.08%MissN/A60 up, 0 downNov 10, 2022$38380
    Jun 30, 2022-$0.44-$0.52-$0.54 - -$0.50+15.38%BeatN/A70 up, 0 downAug 10, 2022$94419
    Mar 31, 2022-$0.49-$0.44-$0.46 - -$0.43-11.36%MissN/A60 up, 0 downMay 10, 2022$183698
    Dec 31, 2021-$0.42-$0.39-$0.47 - -$0.32-7.69%MissN/A50 up, 0 downMar 10, 2022$189591
    Sep 30, 2021-$0.47-$0.62-$0.73 - -$0.46+24.19%BeatN/A4N/ANov 9, 2021$482130
    Jun 30, 2021-$1.61-$1.44-$1.94 - -$0.79-11.81%MissN/A3N/AJul 30, 2021$660040
    Mar 31, 2021-$1.26-$1.25N/A-0.80%MissN/AN/AN/AJun 2, 2021$748200
    Dec 31, 2020-$1.26N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$665080
    Dec 31, 2019-$0.65N/AN/AN/AN/AN/AN/AN/AMar 30, 2020N/A
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.38, after -$2.52 the year before. It was -$0.65 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.38N/A
    Dec 31, 2024-$2.52N/A
    Dec 31, 2023-$1.89N/A
    Dec 31, 2022-$1.92N/A
    Dec 31, 2021-$3.76N/A
    Dec 31, 2020-$1.26N/A
    Dec 31, 2019-$0.65N/A

    Earnings Calls

    The only earnings call listed below, 2025Q3 for the period ended Sep 30, 2025, runs about 5,600 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q3Sep 30, 20255,56210

    2025Q3 Earnings Call

    Opening remarks

    Laurence Watts Investor Relations Thank you, Operator. Joining us on the call today from Immuneering Corporation are Chief Executive Officer, Benjamin Zeskind, Chief Scientific Officer, Brett Hall, Chief Medical Officer, Igor Marchanski, Chief Accounting Officer and Treasurer, Mallory Morales, and Ibi Brakewood, our Chief Business Officer.

    Benjamin Zeskind CEO During this call, management and our two investigators will refer to slides you can find in the updated version of our corporate deck available in PDF on our IR website. Throughout this call, management will be making forward-looking statements, including statements related to its Phase IIa trial of atezvastib as well as the timing of additional data from the study and the company's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its security filings, including its annual report on Form 10-Ks and our quarterly reports on Form 10-Q. Immuneering Corporation undertakes no duty or obligation to update any forward statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to Benjamin Zeskind, Chief Executive Officer of Immuneering Corporation. Ben? Thank you, Laurence. Good afternoon, everyone, and thank you for your interest in Immuneering Corporation. We do not always hold quarterly calls, but we try to do so when we have something interesting to share. And today, we are very fortunate to be joined by two investigators from our Phase 2a trial, who will walk us through two remarkable case studies of first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX. The investigators are Dr. Allison J. Ocean, Professor of Clinical Medicine at the Weill Medical College of Cornell University, and Dr. Gregory Bata, Associate Professor of Medicine at the Moores Cancer Center at UC San Diego. Doctors are, of course, busy individuals who plan to start the call with their respective case studies, after which we will let them get back to their patients. Then we will share a summary of the third quarter and why it was so transformational for Immuneering Corporation. In September, we shared an update on 34 first-line pancreatic cancer patients treated with atebimetinib in combination with gemcitabine nab-paclitaxel, with remarkable overall survival. We are as excited as ever about the overall survival we are seeing in that cohort, and we are very excited to share an update soon. We are currently planning to do so in 2026, possibly at a major medical meeting.

    Frequently Asked Questions About IMRX

    Did IMRX beat earnings estimates last quarter?

    No. Immuneering reported EPS of -$0.37 for the quarter ended Sep 30, 2026, below the -$0.29 estimate by 27.59%.

    What EPS do analysts expect from IMRX next quarter?

    The consensus EPS estimate for Immuneering for the quarter ending Dec 31, 2026 is -$0.35 from 9 analysts, with estimates from -$0.44 to -$0.30.

    How often does IMRX beat earnings estimates?

    Immuneering beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.14%.